Company: BOLT
Filing Date: 2025-03-24
Form Type: 10-K
Source: 0000950170-25-043873
Chunk: 9

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-03-24
Form: 10-K
Item: Item 1
Chunk 9
---
Overview 

We are a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Our pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. Our product candidates use pattern recognition receptors in the innate immune system to help the body recognize tumor cells for a productive anti-cancer response. Our proprietary Boltbody™ ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. We believe this approach has the potential to create products that work with a patient’s own immune system, resulting in anti-cancer efficacy with good tolerability. Having explored more than one thousand distinct linker-payloads and multiple tumor targets, we know the importance of both the linker-payload and the antibody and have developed a library of linker-payloads for use in our own development programs and in our collaborations. We believe that ISACs have the potential to transform the cancer treatment landscape in a way similar to what we’ve seen with antibody-drug conjugates, or ADCs. Many antibodies that target tumor antigens could be made into ISACs, providing us with future opportunities. 

Our first Boltbody ISAC program was trastuzumab imbotolimod, or BDC-1001, targeting a tumor antigen known as human epidermal growth factor receptor 2 (HER2) that is common in many cancers. BDC-1001 demonstrated that the ISAC approach can safely deliver antitumor activity. However, we determined that our first-generation ISAC technology was not efficacious enough to be a commercially viable treatment option for patients in this market. As a result, in May 2024 we discontinued development of BDC-1001 as part of a strategic pipeline prioritization and restructuring plan in order to focus on BDC-3042 and our next-generation Boltbody ISAC program BDC-4182.  

We are working on several Boltbody ISAC programs, both on our own and through our collaborations. BDC-4182 is a Boltbody ISAC targeting claudin 18.2 and we anticipate initiating a clinical trial in the second quarter of this year. Our collaborations broaden our pipeline and help us continue to advance our Boltbody ISAC platform technology while benefiting from our collaboration partners’ resources and expertise. Our Genmab collaboration recently advanced the first program into development, and we continue research on additional programs. Our Toray collaboration continues work on an ISAC targeting Caprin-1, a novel cancer target